Review of: "Meropenem Usage Assessment amid the Antibiotic Resistance Crisis: A Comprehensive Analysis in a Tertiary Care Hospital in Pakistan"

Fakhur Uddin¹

1 Jinnah Post Graduate Medical Centre (JPMC)

Potential competing interests: No potential competing interests to declare.

The study entitled: Meropenem Usage Assessment amid the Antibiotic Resistance Crisis: A Comprehensive Analysis in a Tertiary Care Hospital in Pakistan

The concept is good; this type of work is not commonly produced in this region. There is innovation in the title, but there are some gaps/drawbacks in this study.

- 1. In the study, the place of study is not mentioned, where this was conducted. So the place of study should be mentioned in the title and methodology portion.
- 2. From which institute has he taken the ethical approval?
- Why a single meropenem of the class carbapenems? He may use imipenem and other available carbapenems in Pakistan.
- 4. In the study design, it's cross-sectional, but in the variable, the author has mentioned that "the Patients were monitored for adverse effects, treatment outcomes, and any modifications to therapy throughout their hospitalization." Whereas in results, the author has mentioned a cohort study. So this should be clarified whether it is cross-sectional or cohort. If cohort, then which type of
- 5. Why were the intensive care unit patients excluded? If there is any reason, the author may explain it.
- 6. There is a contradiction in the methodology: in the inclusion criteria "who were admitted to the medical unit" and in the Sampling section, it's "involving regular visits to medical units." It may be rephrased and clearly mentioned which patients were included.
- 7. Data analysis is too short; it may be explained clearly in detail which tests were applied for which variables.
- 8. Patients were monitored for adverse effects, treatment outcomes, and any modifications to therapy throughout their hospitalization. Clinical response was defined as the alleviation of infection symptoms, absence of symptom exacerbation, and clinical stability sustained for at least 24 hours. The above-mentioned variables are missing in the results, so they should be added.

If it is accepted for publication, these changes must be revised and addressed.